ARCTURUS THERAPEUTICS HOLDINGS INC.

ARCT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-65.8M $-80.9M $-29.7M $9.3M $-203.7M $-72.1M $-26.0M $-21.8M
Depreciation & Amortization $3.0M $3.5M $3.0M $1.5M $1.2M $882.0K $684.0K $582.0K
Depreciation
Amortization
Stock-Based Compensation $25.4M $38.0M $34.6M $30.6M $28.9M $6.8M $2.0M $1.3M
Net Cash from Operating Activities $-74.3M $-59.7M $-18.1M $32.0M $-135.0M $-42.9M $-6.4M $-20.8M
Investing Activities
Capital Expenditures $230.0K $648.0K $2.9M $7.7M $3.4M $1.7M $818.0K $1.5M
Business Acquisitions
Net Cash from Investing Activities $-230.0K $-648.0K $-2.9M $-7.7M $-3.4M $-1.7M $-818.0K $22.1M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $13.4M $5.4M $-24.1M $-2.9M $48.0M $436.1M $41.9M $10.2M
Net Change in Cash $-61.1M $-55.0M $-45.1M $21.4M $-90.4M $391.5M $34.6M $11.6M
Free Cash Flow $-74.5M $-60.4M $-21.0M $24.3M $-138.4M $-44.6M $-7.3M $-22.2M